Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Conditions
Keywords
stage I ovarian epithelial cancer, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cavity cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel together with carboplatin works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer.
Detailed description
OBJECTIVES: Primary * Determine whether weekly administration of docetaxel and carboplatin is safer than conventional three-week chemotherapy courses, in terms of reducing the rate of myelosuppression, in patients with stage IC-IV ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Secondary * Determine the quality of life of patients treated with this regimen. * Determine the toxic effects of this regimen in these patients. * Determine the efficacy of this regimen, in terms of clinical response rate, time to disease progression, and findings at second-look surgery, in these patients. OUTLINE: Patients receive docetaxel IV and carboplatin IV on days 1, 8, 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo optional second-look surgery. After completion of 6 courses of chemotherapy (and second-look surgery, if applicable), patients may receive consolidation and/or salvage therapy at the discretion of the investigator. Quality of life is assessed at baseline, before each treatment course, at the completion of study treatment, and then annually for 2 years. After completion of study treatment, patients are followed annually for 2 years. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2 years.
Interventions
DRUGcarboplatin
DRUGdocetaxel
PROCEDUREadjuvant therapy
Sponsors
Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal cavity cancer * Stage IC-IV disease * No borderline or low malignant potential tumors of any stage * Underwent initial surgical management, including staging, of early stage disease or surgical debulking of advanced stage disease\* NOTE: \*Patients may delay surgical debulking, if clinically indicated, until after study entry; these patients may receive several courses of neoadjuvant chemotherapy prior to surgical debulking, but before study entry PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Hemoglobin ≥ 8.0 g/dL * Platelet count ≥ 100,000/mm\^3 Hepatic * Bilirubin normal * Meets 1 of the following criteria: * Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal (ULN) * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN * AP ≤ 5 times ULN AND AST or ALT normal Renal * Not specified Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment * No peripheral neuropathy \> grade 1 * No prior malignancy with a poor prognosis that is at risk of relapse during study participation, as determined by the principal investigator * No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No concurrent chemotherapy for another malignancy Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction rate of myelosuppression | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life as assessed by the Functional Assessment of Cancer Therapy -Ovarian (FACT-O) questionnaire | — |
| Toxicity | — |
| Clinical response rate | — |
| Findings at second look surgery | — |
| Time to disease progression | — |
Countries
United States
Outcome results
None listed